Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 455.54
MASI's Cash to Debt is ranked higher than
78% of the 383 Companies
in the Global Medical Devices industry.

( Industry Median: 4.48 vs. MASI: 455.54 )
MASI' s 10-Year Cash to Debt Range
Min: 0.49   Max: No Debt
Current: 455.54

Equity to Asset 0.77
MASI's Equity to Asset is ranked higher than
81% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 0.65 vs. MASI: 0.77 )
MASI' s 10-Year Equity to Asset Range
Min: -1.01   Max: 0.81
Current: 0.77

-1.01
0.81
F-Score: 6
Z-Score: 10.55
M-Score: -2.25
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 14.57
MASI's Operating margin (%) is ranked higher than
86% of the 371 Companies
in the Global Medical Devices industry.

( Industry Median: 6.50 vs. MASI: 14.57 )
MASI' s 10-Year Operating margin (%) Range
Min: -13.85   Max: 137.71
Current: 14.57

-13.85
137.71
Net-margin (%) 10.67
MASI's Net-margin (%) is ranked higher than
85% of the 371 Companies
in the Global Medical Devices industry.

( Industry Median: 4.82 vs. MASI: 10.67 )
MASI' s 10-Year Net-margin (%) Range
Min: -14.75   Max: 81.05
Current: 10.67

-14.75
81.05
ROE (%) 17.88
MASI's ROE (%) is ranked higher than
96% of the 368 Companies
in the Global Medical Devices industry.

( Industry Median: 5.93 vs. MASI: 17.88 )
MASI' s 10-Year ROE (%) Range
Min: 14.55   Max: 319.21
Current: 17.88

14.55
319.21
ROA (%) 13.31
MASI's ROA (%) is ranked higher than
96% of the 381 Companies
in the Global Medical Devices industry.

( Industry Median: 3.43 vs. MASI: 13.31 )
MASI' s 10-Year ROA (%) Range
Min: -17.07   Max: 114.3
Current: 13.31

-17.07
114.3
ROC (Joel Greenblatt) (%) 81.75
MASI's ROC (Joel Greenblatt) (%) is ranked higher than
97% of the 380 Companies
in the Global Medical Devices industry.

( Industry Median: 13.69 vs. MASI: 81.75 )
MASI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 25.58   Max: 3002.28
Current: 81.75

25.58
3002.28
Revenue Growth (%) 12.50
MASI's Revenue Growth (%) is ranked higher than
87% of the 298 Companies
in the Global Medical Devices industry.

( Industry Median: 5.40 vs. MASI: 12.50 )
MASI' s 10-Year Revenue Growth (%) Range
Min: -19.3   Max: 30.3
Current: 12.5

-19.3
30.3
EBITDA Growth (%) -5.10
MASI's EBITDA Growth (%) is ranked higher than
71% of the 279 Companies
in the Global Medical Devices industry.

( Industry Median: -3.60 vs. MASI: -5.10 )
MASI' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 259.6
Current: -5.1

0
259.6
EPS Growth (%) -5.50
MASI's EPS Growth (%) is ranked higher than
69% of the 262 Companies
in the Global Medical Devices industry.

( Industry Median: -1.70 vs. MASI: -5.50 )
MASI' s 10-Year EPS Growth (%) Range
Min: -33.8   Max: 45.9
Current: -5.5

-33.8
45.9
» MASI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

MASI Guru Trades in Q2 2013

Meridian Funds 609,110 sh (+130.2%)
Joel Greenblatt 136,838 sh (+34.41%)
Ron Baron 2,045,969 sh (+0.09%)
Steven Cohen Sold Out
Paul Tudor Jones Sold Out
Pioneer Investments 366,400 sh (-3.04%)
Jim Simons 457,200 sh (-13.47%)
» More
Q3 2013

MASI Guru Trades in Q3 2013

Ron Baron 2,043,344 sh (-0.13%)
Pioneer Investments 286,545 sh (-21.79%)
Joel Greenblatt 94,545 sh (-30.91%)
Jim Simons 60,600 sh (-86.75%)
» More
Q4 2013

MASI Guru Trades in Q4 2013

Paul Tudor Jones 7,400 sh (New)
Mario Gabelli 34,000 sh (New)
Pioneer Investments 324,995 sh (+13.42%)
Jim Simons Sold Out
Joel Greenblatt 86,888 sh (-8.1%)
Ron Baron 1,370,014 sh (-32.95%)
» More
Q1 2014

MASI Guru Trades in Q1 2014

Jeremy Grantham 83,400 sh (New)
Paul Tudor Jones 24,500 sh (+231.08%)
Mario Gabelli 90,000 sh (+164.71%)
Pioneer Investments 338,961 sh (+4.3%)
Ron Baron 1,366,477 sh (-0.26%)
Joel Greenblatt 38,676 sh (-55.49%)
» More
» Details

Insider Trades

Latest Guru Trades with MASI

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2014-03-31 Reduce -55.49%0.03%$25.37 - $31.88 $ 24.03-16%38676
Mario Gabelli 2014-03-31 Add 164.71%0.01%$25.37 - $31.88 $ 24.03-16%90000
Ron Baron 2013-12-31 Reduce -32.95%0.08%$25.62 - $29.61 $ 24.03-14%1370014
Mario Gabelli 2013-12-31 New Buy0.01%$25.62 - $29.61 $ 24.03-14%34000
Joel Greenblatt 2013-09-30 Reduce -30.91%0.04%$21.55 - $27.04 $ 24.03-3%94545
Meridian Funds 2013-06-30 Add 130.2%0.27%$19.04 - $22.5 $ 24.0314%609110
Joel Greenblatt 2013-06-30 Add 34.41%0.03%$19.04 - $22.5 $ 24.0314%136838
Meridian Funds 2013-03-31 New Buy0.19%$19.51 - $21.33 $ 24.0319%264600
Joel Greenblatt 2013-03-31 Add 64.59%0.04%$19.51 - $21.33 $ 24.0319%101804
Joel Greenblatt 2012-12-31 Add 30.93%0.02%$20.22 - $24.11 $ 24.0311%61854
Joel Greenblatt 2012-09-30 Reduce -50.15%0.08%$21 - $24.87 $ 24.035%47242
John Burbank 2012-06-30 Sold Out 0.08%$18.35 - $23.98 $ 24.0315%0
Joel Greenblatt 2012-06-30 Add 36.65%0.04%$18.35 - $23.98 $ 24.0315%94762
John Burbank 2012-03-31 New Buy0.08%$18.46 - $23.49 $ 24.0319%100000
Joel Greenblatt 2012-03-31 Add 110.46%0.07%$18.46 - $23.49 $ 24.0319%69345
Joel Greenblatt 2011-12-31 Add 74.44%0.03%$17.84 - $22.87 $ 24.0316%32950
Joel Greenblatt 2011-09-30 New Buy0.07%$20.96 - $30.91 $ 24.03-5%18889
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 21.60
MASI's P/E(ttm) is ranked higher than
89% of the 411 Companies
in the Global Medical Devices industry.

( Industry Median: 67.30 vs. MASI: 21.60 )
MASI' s 10-Year P/E(ttm) Range
Min: 16.96   Max: 91.05
Current: 21.6

16.96
91.05
P/B 3.90
MASI's P/B is ranked higher than
66% of the 411 Companies
in the Global Medical Devices industry.

( Industry Median: 3.60 vs. MASI: 3.90 )
MASI' s 10-Year P/B Range
Min: 3.54   Max: 15.2
Current: 3.9

3.54
15.2
P/S 2.50
MASI's P/S is ranked higher than
73% of the 411 Companies
in the Global Medical Devices industry.

( Industry Median: 3.28 vs. MASI: 2.50 )
MASI' s 10-Year P/S Range
Min: 1.77   Max: 9.79
Current: 2.5

1.77
9.79
PFCF 35.60
MASI's PFCF is ranked higher than
83% of the 411 Companies
in the Global Medical Devices industry.

( Industry Median: 2429.50 vs. MASI: 35.60 )
MASI' s 10-Year PFCF Range
Min: 2.29   Max: 69.58
Current: 35.6

2.29
69.58
EV-to-EBIT 14.31
MASI's EV-to-EBIT is ranked higher than
90% of the 411 Companies
in the Global Medical Devices industry.

( Industry Median: 44.62 vs. MASI: 14.31 )
MASI' s 10-Year EV-to-EBIT Range
Min: 6.3   Max: 117.2
Current: 14.31

6.3
117.2
PEG 108.40
MASI's PEG is ranked higher than
82% of the 411 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. MASI: 108.40 )
MASI' s 10-Year PEG Range
Min: 0.38   Max: 107.5
Current: 108.4

0.38
107.5
Shiller P/E 22.90
MASI's Shiller P/E is ranked higher than
95% of the 411 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. MASI: 22.90 )
MASI' s 10-Year Shiller P/E Range
Min: 14.04   Max: 31.15
Current: 22.9

14.04
31.15
Current Ratio 2.96
MASI's Current Ratio is ranked higher than
71% of the 379 Companies
in the Global Medical Devices industry.

( Industry Median: 2.94 vs. MASI: 2.96 )
MASI' s 10-Year Current Ratio Range
Min: 1.35   Max: 4.87
Current: 2.96

1.35
4.87
Quick Ratio 2.38
MASI's Quick Ratio is ranked higher than
73% of the 379 Companies
in the Global Medical Devices industry.

( Industry Median: 2.19 vs. MASI: 2.38 )
MASI' s 10-Year Quick Ratio Range
Min: 1.15   Max: 4.34
Current: 2.38

1.15
4.34

Valuation & Return

vs
industry
vs
history
Price/Net Cash 109.20
MASI's Price/Net Cash is ranked higher than
82% of the 411 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. MASI: 109.20 )
MASI' s 10-Year Price/Net Cash Range
Min: 13.94   Max: 2566
Current: 109.2

13.94
2566
Price/Net Current Asset Value 13.40
MASI's Price/Net Current Asset Value is ranked higher than
85% of the 411 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. MASI: 13.40 )
MASI' s 10-Year Price/Net Current Asset Value Range
Min: 9.32   Max: 41.2
Current: 13.4

9.32
41.2
Price/Tangible Book 4.50
MASI's Price/Tangible Book is ranked higher than
72% of the 411 Companies
in the Global Medical Devices industry.

( Industry Median: 6.18 vs. MASI: 4.50 )
MASI' s 10-Year Price/Tangible Book Range
Min: 4.11   Max: 15.3
Current: 4.5

4.11
15.3
Price/DCF (Projected) 1.40
MASI's Price/DCF (Projected) is ranked higher than
94% of the 411 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. MASI: 1.40 )
MASI' s 10-Year Price/DCF (Projected) Range
Min: 1.22   Max: 2.5
Current: 1.4

1.22
2.5
Price/Median PS Value 0.70
MASI's Price/Median PS Value is ranked higher than
91% of the 411 Companies
in the Global Medical Devices industry.

( Industry Median: 1.18 vs. MASI: 0.70 )
MASI' s 10-Year Price/Median PS Value Range
Min: 0.6   Max: 2.64
Current: 0.7

0.6
2.64
Price/Graham Number 2.10
MASI's Price/Graham Number is ranked higher than
85% of the 411 Companies
in the Global Medical Devices industry.

( Industry Median: 8.75 vs. MASI: 2.10 )
MASI' s 10-Year Price/Graham Number Range
Min: 1.76   Max: 5.96
Current: 2.1

1.76
5.96
Earnings Yield (Greenblatt) 6.90
MASI's Earnings Yield (Greenblatt) is ranked higher than
83% of the 287 Companies
in the Global Medical Devices industry.

( Industry Median: 4.90 vs. MASI: 6.90 )
MASI' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.9   Max: 15.8
Current: 6.9

0.9
15.8
Forward Rate of Return (Yacktman) 4.03
MASI's Forward Rate of Return (Yacktman) is ranked higher than
82% of the 302 Companies
in the Global Medical Devices industry.

( Industry Median: 0.90 vs. MASI: 4.03 )
MASI' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 3.2   Max: 64.3
Current: 4.03

3.2
64.3

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:3M4.Germany
Masimo Corporation was incorporated in California in May 1989 and reincorporated in Delaware in May 1996. On August 13, 2007, the Company completed its initial public offering. It is a global medical technology company that develops, manufactures and markets noninvasive patient monitoring products that improve patient care. The Company develops, manufactures, and markets a family of noninvasive blood constituent patient monitoring solutions that consists of a monitor or circuit board and its proprietary single-patient use and reusable sensors and cables. In addition, it offers remote monitoring and clinician notification solutions, such as the Masimo Patient SafetyNet. It solutions and related products are based upon the proprietary Masimo SET algorithms. The Company invented Masimo Signal Extraction Technology, or Masimo SET, which provides the capabilities of Measure-Through Motion and Low Perfusion pulse oximetry to address the primary limitations of conventional pulse oximetry. Pulse oximetry is the noninvasive measurement of the oxygen saturation level of arterial blood, or the blood that delivers oxygen to the body's tissues, and pulse rate. The Company's Masimo SET platform has addressed many of the previous technology limitations and has been referred to by several industry sources as the gold standard in pulse oximetry. The benefits of Masimo SET have been validated in over 100 independent clinical and laboratory studies. This software-based technology is incorporated into a variety of product platforms depending on its customers' specifications. The Company's Masimo SET MS circuit boards perform all signal processing and other pulse oximetry functions incorporating the Masimo SET platform. It next-generation circuit board is the foundation for the Masimo Rainbow SET Pulse CO-Oximetry platform, utilizing technology licensed from Masimo Labs. The MX circuit boards measure arterial blood oxygen saturation levels and pulse rate, and have the circuitry to enable the measurement of total hemoglobin, oxygen content, carboxyhemoglobin, methemoglobin, PVI, and acoustic respiration rate, along with other potential parameters in the future. The Radical-7 incorporates the MX circuit board, which enables Rainbow SET parameters, and offers three-in-one capability to be used as: a standalone device for bedside monitoring; a detachable, battery-operated handheld unit for easy portable monitoring; and a monitor interface via SatShare, proprietary technology allowing its products to work with certain competitor products, to upgrade existing conventional multi-parameter patient monitors to Masimo SET while displaying Rainbow parameters on the Radical-7 itself. The Rad-87, which also contains Masimo Rainbow SET technology, is a compact, lightweight and easy-to-use device designed specifically for use in less acute settings than the Radical-7. The Rad-8 is a bedside pulse oximeter featuring Masimo SET with a low cost design and streamlined
» More Articles for MASI

Headlines

Articles On GuruFocus.com
Meridian Funds' Top Five Second Quarter Increases Jul 30 2013 
Growth wise it looks Mar 18 2013 
Weekly CEO Buys Highlight: MDR, MASI, FCH, FGP, FUR Jun 10 2012 
Masimo Corp. CEO Joe Kiani Buys 50,000 Shares Jun 04 2012 
Comment for Jun 02 2012 
Weekly CEO Buys Highlight: KMI, VGR, SIRO, PNK, MASI Nov 27 2011 
Weekly CEO Buys Highlight: SLM, MASI, ITRI, FLS, PG Nov 05 2011 
Weekly CEO Buys Highlight: MASI, ITRI, FSL, PTP, SLB Oct 29 2011 
Masimo Corp. Reports Operating Results (10-K) Feb 16 2011 
Masimo Corp. Reports Operating Results (10-Q) Nov 03 2010 


More From Other Websites
Masimo to Report Second Quarter 2014 Financial Results After Market Close on Thursday, August 7th Jul 21 2014
Masimo to Report Second Quarter 2014 Financial Results After Market Close on Thursday, August 7th Jul 21 2014
New Study Evaluates Trending Accuracy and Reliability of Masimo's Continuous and Noninvasive SpHb(R)... Jul 09 2014
UPDATE: BTIG Initiates Coverage On Masimo, Sees 31% Premium To Shares Jul 08 2014
MASIMO CORP Files SEC form 8-K, Change in Directors or Principal Officers Jul 03 2014
Alphatec Holdings (ATEC) Soars: Stock Adds 13.2% in Session Jul 01 2014
Masimo Announces FDA Clearance of Root (TM) Patient Monitoring Platform With Capnography, IRIS(TM)... Jun 30 2014
Masimo annonce son soutien au plan d'action Chaque nouveau-né (ENAP) visant à réduire la... Jun 29 2014
Masimo Announces Support for the Every Newborn Action Plan to Reduce Global Newborn Mortality Jun 27 2014
Masimo Announces Support for the Every Newborn Action Plan to Reduce Global Newborn Mortality Jun 27 2014
Masimo Announces TFA-1(TM) Transflectance Adhesive Forehead Sensor Jun 25 2014
New Study of Masimo Noninvasive and Continuous SpHb(R) Monitoring Demonstrates Accuracy and Utility... Jun 18 2014
Cimarex Energy to Join the S&P 500; Changes to the S&P MidCap 400 and the S&P SmallCap 600 Jun 12 2014
New Study Shows Masimo Noninvasive SpCO(R) Helps Clinicians Increase Detection of Carbon Monoxide... Jun 11 2014
MASIMO CORP Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Jun 11 2014
Masimo Gains on Positive PVI & SpHb Study Data Jun 10 2014
Two Randomized Trials Presented at the Euroanaesthesia 2014 Congress Show Similar Fluid... Jun 06 2014
Omnicell Retains Balanced View May 29 2014
Masimo annonce l'apposition du marquage CE sur son oxymètre de pouls iSpO2(TM) Rx pour appareils... May 29 2014
Masimo announces CE Mark of iSpO2 Rx Pulse Oximeter for mobile devices May 29 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide